GSK has delivered a solid multi year share price run, helped by fresh moves in oncology and vaccines, and that raises a ...

On Monday, GSK plc GSK stock is trading higher on highly positive clinical data from two separate lung cancer trials, ...

GSK stock rose 0.4% after Berenberg upgraded to buy with a £22 target and GSK announced a $750M deal with Chimagen Biosciences for a multiple myeloma asset.

According to Sharecast on September 18, 2026, Berenberg upgraded GSK from Hold to Buy and lifted its target price on the stock from GBP 20 to GBP 22, arguing that recent business-development ...

GSK stock increased 0.4% following Berenberg's upgrade to buy with £22 target and announcement of $750M Chimagen deal for multiple myeloma therapy.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

GSK GSK shares have lost 8.8% in a month, mainly because investors were disappointed with the company maintaining guidance instead of raising it despite reporting strong first-quarter 2026 results.

Since I last checked on the British pharmaceuticals' stock GSK (GSK) in December last year, its price has risen by 12%. Interestingly, this is despite the stock having lost 11% of its value since the ...

GSK delivered healthy Q2 and H1 2026 results, with the highlight being core turnover and EPS growth at the upper end of the guidance ranges. However, it's hard to make a Buy case for it anymore as ...

GSK stock in London traded around 1,858.5 pence on September 15, 2026 after the company agreed a deal worth up to USD 750 million for a blood cancer drug. Berenberg raised its rating to Buy and lifted ...